Farmas USA

OCAT
A ver sí acierto donde hace suelo y acumulo alguna más. Digamos que son parte de los prófits de NVAX, no tengo prisa pero tampoco quiero perderlos y si sacarles una buena tajada.

campeon, se esta haciendo dificil superar tu marca de venta de las NVAX !!! 

caguen tó!

:)

Novavax to Present at the Wedbush PacGrow Healthcare Conference
Date: Wednesday, August 12, 2015

Time: 12:45 p.m. US Eastern Time
Location: Le Parker Meridian hotel, New York City
Live webcast: http://wsw.com/webcast/wedbush30/nvax

The webcast and a replay of the presentation will also be accessible under the “Investors/Events” section of the Novavax website at novavax.com.

NVAX

Arena Pharmaceuticals (NASDAQ:ARNA): Q2 EPS of -$0.11 beats by $0.03.
revenue of $9.18M (-28.3% Y/Y) misses by $1.77M.

ARNA

Ya llegará esa y mucho más. Yo sí vuelve a 11 o 10,xx recompro.
Pero con las OCAT llevo un buen mamporro

ATNM
Company Update (NYSEMKT:ATNM): Actinium Pharmaceuticals Inc Issues Letter to Shareholders Outlining Measures to Move Iomab-B and Actimab-A Into Advanced Development
SHARE ON:
Corey Williams — August 5, 2015, 3:03 PM EDT

Actinium Pharmaceuticals Inc (NYSEMKT:ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that it has it has issued a letter to shareholders providing an update on the progress it has made to advance its two drug candidates, Iomab-B and Actimab-A, towards commercialization. With a substantially stronger balance sheet following financing activity that yielded cash in excess of $25 million at June 30, 2015, the Company is well positioned to propel forward its research activities and transition its key programs with Iomab-B and Actimab-A through value creating milestones.

Highlights of the letter include:

Successfully completed the third cohort of AML (Acute Myeloid Leukemia) patients in Phase 1/2 trial for Actimab-A, in which patients received two doses of Actimab-A at 1.5 μCi/kg per dose compared to a lower dose of 1.0 μCi/kg that patients received in Cohort 2. Two out of three Actimab-A treated patients achieved complete remission in Cohort 3, with different degrees of hematological recovery (CRi). By comparison, one patient achieved Cri in Cohort 2.
Launched the enrollment process for Cohort 4 for Actimab-A and activated more medical centers to facilitate patient enrollment. With encouraging results observed as Phase 1 progressed, the Company anticipates strong support from this network as it enrolls patients for Phase 2.
Resolved an unexpected manufacturing problem through increased oversight of the production process. This has also generated valuable intellectual property, know-how and trade secrets that will further protect the Iomab-B process.
Submitted a request to the FDA (Food and Drug Administration) for a pre-IND meeting for Iomab-B. The FDA typically responds within 60 days of receiving an application.  Ramped up business development efforts to find suitable partners for both products to support their development and future commercial launch. (Original Source)
Shares of Actinium Pharmaceuticals opened today at $1.73 and are currently trading up at $1.9177. ATNM has a 1-year high of $8.12 and a 1-year low of $1.52. The stock’s 50-day moving average is $2.46 and its 200-day moving average is $3.05.

Report financiero el día 10 para nuestra amiga MNkD, y hablaran
de los desarrollos de la compañía.
En el anterior report y después de los resultados, downgrade de JPM
y batacazo...Con unas ventas de 7M pero solo contabilizadas desde
febrero.
Igual la podemos pescar a buen precio a está joyita...
Ahora que como sean buenos se nos lanza al alza rapidito.
Y sin compararlo con el anterior trimestre...que tiene trampa...jajaja.

Acaban de bajarla a 0.78 en el AH. Espero que recupere, porque son pocos cromos.

XOMA

EDIT: Ya ha vuelto a 0.9